Addendum
Alectinib (NSCLC, adjuvant) – Addendum to Project A24-73
Report documents
-
Addendum
Alectinib (NSCLC, adjuvant) – Addendum to Project A24-73
Dossier assessment
Indication:
Adjuvant treatment following complete tumour resection for adult patients with anaplastic lymphoma kinase-positive non-small cell lung cancer at high risk of recurrence
Result of dossier assessment:
- Patients for whom adjuvant platinum-based chemotherapy is suitable: Unchanged after addendum: added benefit not proven
- Patients after prior platinum-based chemotherapy or patients for whom this therapy is not suitable: Unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2025-01-16 A G-BA decision was published.
Project details
- Project no.
- A24-115
- Commission
- Commission awarded on 26.11.2024 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A24-115_en
Connected Projects
-
Dossier assessment
Alectinib (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed